Theriva Biologics, Inc. Nov 22, 2026 Copy link Theriva™ Biologics Announces Reverse Stock Split ROCKVILLE, Md., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified Business
Theriva Biologics, Inc. Nov 12, 2026 Copy link Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results – VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 – – Company completes sale of Business
Theriva Biologics, Inc. Nov 2, 2026 Copy link Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. – Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales Business
Theriva Biologics, Inc. Sep 30, 2026 Copy link Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued Business
Theriva Biologics, Inc. Aug 11, 2026 Copy link Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 Business
Theriva Biologics, Inc. Aug 6, 2026 Copy link Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Business
Theriva Biologics, Inc. Jul 7, 2026 Copy link Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Business
Theriva Biologics, Inc. Jun 11, 2026 Copy link Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research – Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Business